


In the Claims

This listing of the claims reflects the claims as currently pending in the application.

1. (original) A method of inhibiting a transforming growth factor $\beta 2$ (TGF $\beta 2$) comprising contacting said TGF $\beta 2$ with a nucleic acid ligand of TGF $\beta 2$.
2. (previously presented) The method of claim 1, wherein the nucleic acid ligand of TGF $\beta 2$ comprises a ligand having a nucleotide sequence selected from SEQ ID NO: 115.
3. (original) The method of claim 1 wherein said nucleic acid ligand is conjugated to polyethylene glycol (PEG).
4. (original) The method of claim 3 wherein said PEG has a molecular weight of about between 10-80 K.
5. (original) The method of claim 3 wherein said PEG has a molecular weight of about 20-45 K.
6. (original) The method of claim 1 wherein said ligand is



wherein

X=PEG, and

LIGAND=
rGrGrArGrGfUfUrAfUfUrAfCrArGrArGfUfCfUrGfUfUrArGfCfUrGfUfAfCfUfCfC-3'-3'-dT
(SEQ ID NO:115), wherein rG is 2'OH G, rA is 2'OH A, fU is 2'F U and fC is 2'F C.

7. (previously presented) A method for targeting a nucleic acid ligand of TGF β 2 to a site in a patient comprising TGF β 2 comprising:

covalently linking said nucleic acid ligand to a Non-Immunogenic, High Molecular Weight Compound or Lipophilic Compound to form a Complex, and administering said Complex to said patient, whereby said nucleic acid ligand is targeted to a site in a patient comprising TGF β 2.


8. (previously presented) The method of claim 7, wherein the nucleic acid ligand of TGF β 2 comprises a ligand having a nucleotide sequence selected from the group consisting of SEQ ID NO: 115.

9. (original) The method of claim 7 wherein said nucleic acid ligand is conjugated to polyethylene glycol (PEG).

10. (original) The method of claim 9 wherein said PEG has a molecular weight of about between 10-80 K.

11. (original) The method of claim 9 wherein said PEG has a molecular weight of about 20-45 K.

12. (original) The method of claim 7 wherein said ligand is



wherein

X=PEG, and

LIGAND=
 rGrGrArGrGfUfUrAfUfUrAfCrArGrArGfUfCfUfGfUfUrArGfCfUrGfUrAfCfUfCfC-3'-3'-dT
 (SEQ ID NO:115), wherein rG is 2'OH G, rA is 2'OH A, fU is 2'F U and fC is 2'F C.

13. (previously presented) A method for treating TGFβ2-mediated pathological conditions comprising administering a nucleic acid ligand capable of binding to TGFβ2 to a patient in need thereof.


14. (previously presented) The method of claim 13, wherein the nucleic acid ligand of TGFβ2 - comprises a ligand having a nucleotide sequence selected from the group consisting of SEQ ID NO: 115.

15. (original) The method of claim 13 wherein said nucleic acid ligand is conjugated to polyethylene glycol (PEG).

16. (original) The method of claim 15 wherein said PEG has a molecular weight of about between 10-80 K.

17. (original) The method of claim 15 wherein said PEG has a molecular weight of about 20-45 K.

18. (original) The method of claim 13 wherein said ligand is



wherein

X=PEG, and

LIGAND=
rGrGrArGrGfUfUrAfUfUrAfCrArGrArGfUfCfUrGfUfUrArGfCfUrGfUrAfCfUfCfC-3'-3'-dT
(SEQ ID NO:115), wherein rG is 2'OH G, rA is 2'OH A, fU is 2'F U and fC is 2'F C.